# Filing Detail

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-26-049412
Filing Date
2026-04-29
Accepted
2026-04-29 17:19:51
Documents
245
Period of Report
2025-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | ANNUAL REPORT | ea0285148-20f_ascentage.htm iXBRL | 20-F | 6558208
2 | DESCRIPTION OF SECURITIES | ea028514801ex2-4.htm | EX-2.4 | 276254
3 | POST-IPO SHARE OPTION PLAN AS AMENDED ON MAY 19, 2025 | ea028514801ex4-5.htm | EX-4.5 | 167804
4 | 2021 RSU SCHEME AS AMENDED ON MAY 19, 2025 | ea028514801ex4-8.htm | EX-4.8 | 147702
5 | AMENDED AND RESTATED AMENDED PATENT LICENSE AGREEMENT BETWEEN ASCENTAGE PHARMA G | ea028514801ex4-12.htm | EX-4.12 | 113309
6 | LICENSE AGREEMENT BETWEEN ASCENTAGE PHARMA GROUP CORP LIMITED AND THE REGENTS OF | ea028514801ex4-13.htm | EX-4.13 | 110363
7 | OFFER LETTER BETWEEN ASCENTAGE PHARMA GROUP INC. AND VEET MISRA | ea028514801ex4-15.htm | EX-4.15 | 23806
8 | LIST OF SUBSIDIARIES OF THE REGISTRANT | ea028514801ex8-1.htm | EX-8.1 | 5059
9 | ENGLISH TRANSLATION OF ASCENTAGE PHARMA GROUP INTERNATIONAL INSIDER TRADING POLI | ea028514801ex11-1.htm | EX-11.1 | 150794
10 | CERTIFICATION | ea028514801ex12-1.htm | EX-12.1 | 13568
11 | CERTIFICATION | ea028514801ex12-2.htm | EX-12.2 | 13790
12 | CERTIFICATION | ea028514801ex13-1.htm | EX-13.1 | 4596
13 | CERTIFICATION | ea028514801ex13-2.htm | EX-13.2 | 6263
14 | CONSENT OF ERNST & YOUNG HUA MING LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING | ea028514801ex15-1.htm | EX-15.1 | 3710
15 | CONSENT OF WALKERS (HONG KONG) | ea028514801ex15-2.htm | EX-15.2 | 7146
16 | CONSENT OF JUNHE LLP | ea028514801ex15-3.htm | EX-15.3 | 4407
17 | CONSENT OF FROST & SULLIVAN | ea028514801ex15-4.htm | EX-15.4 | 4763
18 | ASCENTAGE PHARMA GROUP INTERNATIONAL COMPENSATION RECOVERY POLICY | ea028514801ex97-1.htm | EX-97.1 | 45941
19 | GRAPHIC | ea028514801_img1.jpg | GRAPHIC | 95123
20 | GRAPHIC | ea028514801_img2.jpg | GRAPHIC | 82665
21 | GRAPHIC | ea028514801_img3.jpg | GRAPHIC | 83252
22 | GRAPHIC | ea028514801_img4.jpg | GRAPHIC | 82665
23 | GRAPHIC | ea028514801_img5.jpg | GRAPHIC | 85036
24 | GRAPHIC | ea028514801_img6.jpg | GRAPHIC | 160078
25 | GRAPHIC | ea028514801_img7.jpg | GRAPHIC | 63196
26 | GRAPHIC | ea028514801_img8.jpg | GRAPHIC | 238794
27 | GRAPHIC | ea028514801_img9.jpg | GRAPHIC | 449108
28 | GRAPHIC | ea028514801_img10.jpg | GRAPHIC | 235365
29 | GRAPHIC | ea028514801_img11.jpg | GRAPHIC | 139524
30 | GRAPHIC | ea028514801_img12.jpg | GRAPHIC | 180096
31 | GRAPHIC | ea028514801_img13.jpg | GRAPHIC | 69452
32 | GRAPHIC | ea028514801_img14.jpg | GRAPHIC | 72390
33 | GRAPHIC | ea028514801_img15.jpg | GRAPHIC | 72421
34 | GRAPHIC | ea028514801_img16.jpg | GRAPHIC | 50532
35 | GRAPHIC | ea028514801_img17.jpg | GRAPHIC | 55485
36 | GRAPHIC | ea028514801_img18.jpg | GRAPHIC | 49439
37 | GRAPHIC | ea028514801_img19.jpg | GRAPHIC | 76595
38 | GRAPHIC | ea028514801_img20.jpg | GRAPHIC | 298936
39 | GRAPHIC | ea028514801_img21.jpg | GRAPHIC | 304105
40 | GRAPHIC | ea028514801_img22.jpg | GRAPHIC | 202725
41 | GRAPHIC | ea028514801_img23.jpg | GRAPHIC | 203777
42 | GRAPHIC | ea028514801_img24.jpg | GRAPHIC | 173003
43 | GRAPHIC | ea028514801_img25.jpg | GRAPHIC | 15831
44 | GRAPHIC | ea028514801_img26.jpg | GRAPHIC | 15152
45 | GRAPHIC | ea028514801_img27.jpg | GRAPHIC | 15225
46 | GRAPHIC | ea028514801_img28.jpg | GRAPHIC | 18408
47 | GRAPHIC | ea028514801_img29.jpg | GRAPHIC | 22417
48 | GRAPHIC | ea028514801_img30.jpg | GRAPHIC | 22079
49 | GRAPHIC | ea028514801_img31.jpg | GRAPHIC | 9740
50 | GRAPHIC | ea028514801_img32.jpg | GRAPHIC | 10029
51 | GRAPHIC | ea028514801_img33.jpg | GRAPHIC | 13546
52 | GRAPHIC | ea028514801_img34.jpg | GRAPHIC | 27152
53 | GRAPHIC | ea028514801_img35.jpg | GRAPHIC | 22240
54 | GRAPHIC | ea028514801_ex4-15img1.jpg | GRAPHIC | 4647
55 | GRAPHIC | ea028514801_ex15-2img1.jpg | GRAPHIC | 1843
56 | GRAPHIC | ea028514801_ex15-4img1.jpg | GRAPHIC | 54962
| Complete submission text file | 0001213900-26-049412.txt |  | 35527903

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
57 | XBRL SCHEMA FILE | aapg-20251231.xsd | EX-101.SCH | 207849
58 | XBRL CALCULATION FILE | aapg-20251231_cal.xml | EX-101.CAL | 111801
59 | XBRL DEFINITION FILE | aapg-20251231_def.xml | EX-101.DEF | 707710
60 | XBRL LABEL FILE | aapg-20251231_lab.xml | EX-101.LAB | 1227615
61 | XBRL PRESENTATION FILE | aapg-20251231_pre.xml | EX-101.PRE | 743985
249 | EXTRACTED XBRL INSTANCE DOCUMENT | ea0285148-20f_ascentage_htm.xml | XML | 5288930

Mailing Address 68 XINQING ROAD SUZHOU INDUSTRIAL PARK SUZHOU , JIANGSU China
Business Address 68 XINQING ROAD SUZHOU INDUSTRIAL PARK SUZHOU , JIANGSU China 86 512 8555 7777
ASCENTAGE PHARMA GROUP INTERNATIONAL (Filer) CIK: 0002023311 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-42484 | Film No.: 26918112
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)